Synthesis and structure-activity relationships of potent thrombin inhibitors: Piperazides of 3-amidinophenylalanine

Journal of Medicinal Chemistry

Volumn 40, Issue 19, 1997, Pages 3091-3099

  Stürzebecher, Jörg ^a   Prasa, Dagmar ^a   Hauptmann, Jörg ^a   Vieweg, Helmut ^b   Wikström, Peter ^b  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b Pentapharm Ltd   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

HIRUDIN; N ALPHA [(2 NAPHTHYLSULFONYL)GLYCYL] 4 AMIDINOPHENYLALANYLPIPERIDIDE; THROMBIN; THROMBIN INHIBITOR; UNCLASSIFIED DRUG;

ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CRYSTAL STRUCTURE; DRUG BIOAVAILABILITY; DRUG POTENCY; DRUG STRUCTURE; PROTEIN DEGRADATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; THROMBOSIS; X RAY CRYSTALLOGRAPHY;

ANIMALS; ANTITHROMBINS; BINDING SITES; BLOOD COAGULATION; CRYSTALLOGRAPHY, X-RAY; DIPEPTIDES; FACTOR XA; HUMANS; INDICATORS AND REAGENTS; METABOLIC CLEARANCE RATE; PHENYLALANINE; PIPERAZINES; PIPERIDINES; PLASMIN; PROTEASE INHIBITORS; PROTHROMBIN TIME; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; TRYPSIN;

EID: 0030768740     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm960668h     Document Type: Article

References (36)

1. Sixma, J. J.; de Groot, P. G. The ideal anti-thrombotic drug. Thromb. Res. 1992, 68, 507-512.
2. Powers, J. C.; Kam, C.-M. Synthetic substrates and inhibitors of thrombin. In Thrombin. Structure and Function; Berliner, L. J., Ed.; Plenum Press: New York, 1992; pp 117-158.
3. Harker, L. A.; Hanson, S. R.; Kelly, A. B. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists. Thromb. Haemostas. 1995, 74, 464-472.
4. Stone, S. Thrombin inhibitors - A new generation of antithrombotics. Trends Cardiovasc. Med. 1995, 5, 134-140.
5. Markwardt, F. The development of hirudin as an antithrombotic drug. Thromb. Res. 1994, 74, 1-23.
6. Maraganore, J. M.; Bourdon, P.; Jablonski, J.; Ramachandran, K. L.; Fenton, J. W., II Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin. Biochemistry 1990, 29, 7095-7101.
7. Bagdy, D.; Barabas, E.; Szabo, G.; Bajusz, S.; Szell, E. In vivo anticoagulant and antiplatelet effect of D-Phe-Pro-Arg-H and D-Me-Phe-Pro-Arg-H. Thromb. Haemostas. 1992, 67, 357-365.
8. Hussain, M. A.; Knabb, R.; Aungst, B. J.; Kettner, C. Anticoagulant activity of a peptide boronic acid thrombin inhibitor by various routes of administration in rats. Peptides 1991, 12, 1153-1154.
9. Stürzebecher, J.; Prasa, D.; Bretschneider, E.; Bode, W.; Bauer M.; Brandstetter, H.; Wikström, P.; Vieweg, H. New develop-ments in the field of benzamidine-derived thrombin inhibitors. In DIC - Pathogenesis, Diagnosis and Therapy of Disseminated Intravascular Fibrin Formation; Müller-Berghaus, G., Madlener, K., Blombäck, M., ten Gate, J. W., Eds.; Excerpta Medica: Amsterdam, London, New York, Tokyo, 1993; pp 183-190.
10. Kimball, S. D. Challenges in the development of orally bioavailable thrombin active site inhibitors. Blood Coag. Fibrinol. 1995, 6, 511-519.
11. Hauptmann, J.; Kaiser, B.; Paintz, M.; Markwardt, F. Biliary excretion of synthetic benzamidine-type thrombin inhibitors in rabbit and rats. Biomed. Biochim. Acta 1987, 46, 445-453.
12. Hauptmann, J.; Kaiser, B. In vitro and in vivo comparison of arginine- and benzamidine-derived highly potent synthetic thrombin inhibitors. Pharmazie 1991, 46, 57-58.
13. Eriksson, U. G.; Renberg, L.; Vedin, C.; Strimfors, M. Pharmacokinetics of inogatran, a new low molecular weight thrombin inhibitor, in rats and dogs. Thromb. Haemostas. 1995, 73, 1605.
14. Markwardt, F.; Wagner, G.; Stürzebecher, J.; Walsmann, P. Nα-Arylsulfonyl-ω-(4-amidinophenyl)-α-aminoalkylcarboxylic acid amides - novel selective inhibitors of thrombin. Thromb. Res. 1980, 17, 425-431.
15. Stürzebecher, J.; Markwardt, F.; Voigt, B.; Wagner, G.; Walsmann, P. Cyclic amides of Nα-arylsulfonylaminoacylated 4-amidinophenylalanine - tight binding inhibitors of thrombin. Thromb. Res. 1983, 29, 635-642.
16. Reers, M.; Koschinsky, R.; Dickneite, G.; Hoffmann, D.; Czech, J.; Stüber, W. Synthesis and characterisation of novel thrombin inhibitors based on 4-amidinophenylalanine. J. Enzyme Inhib. 1995, 9, 61-72.
17. Kaiser, B.; Hauptmann, J.; Weiss, A.; Markwardt, F. Pharmacological characterization of a new highly effective synthetic thrombin inhibitor. Biomed. Biochim. Acta 1985, 44, 1201-1210.
18. Dickneite, G.; Seiffge, D.; Diehl, K. H.; Reers, M.; Czech, J.; Weinmann, E.; Hoffmann, D.; Stüber, W. Pharmacological characterization of a new 4-amidinophenylalanine thrombin inhibitor (CRC 220). Thromb. Res. 1995, 77, 357-368.
19. Stürzebecher, J.; Horn, H.; Walsmann, P.; Voigt, B.; Markwardt, F.; Wagner, G. Synthetische Inhibitoren der Serinproteinasen. 34. Mittg.: Einfluss der Abwandlung der Amidinofunktion bei Nα-substituierten 4-Amidinophenylalaninamiden auf die Inhibitoraktivität. (Synthetic inhibitors of serine proteinases. Part 34: Influence of modification of the amidino function of Nα-substituted 4-amidinophenylalanine amides on the inhibitory activity.) Pharmazie 1988, 43, 782-783.
20. Bode, W.; Turk, D.; Stürzebecher, J. Geometry of binding of benzamidine and arginine-based inhibitors NAPAP and MQPA to human α-thrombin: X-ray crystallographic determination of the NAPAP-trypsin complex and modeling of NAPAP-thrombin and MQPA-thrombin. Eur. J. Biochem. 1990, 193, 175-182.
21. Bauer, M.; Brandstetter, H.; Turk, D.; Stürzebecher, J.; Bode, W. Crystallographic determination of thrombin complexes with small synthetic inhibitors as starting point for the receptor-based design of antithrombotics. Semin. Thromb. Hemostas. 1993, 19, 352-360.
22. Turk, D.; Stürzebecher, J.; Bode, W. Geometry of binding of the Nα-tosylated piperidides of m-amidino-, p-amidino- and p-guanidino phenylalanine to trypsin and thrombin complexes. FEBS Lett. 1991, 287, 133-138.
23. Brandstetter, H.; Turk, D.; Hoeffken, H. W.; Grosse, D.; Stürzebecher, J.; Martin, P. D.; Edwards, B. F. P.; Bode, W. Refined 2.3 Å X-ray crystal structure of bovine thrombin complexes formed with the benzamidine and arginine-based thrombin inhibitors NAPAP, 4-TAPAP and MQPA. J. Mol. Biol. 1992, 226, 1085-1099.
24. Stürzebecher, J.; Vieweg, H.; Wikström, P. WO 92/08709, 1991.
25. Stürzebecher, J.; Prasa, D.; Wikström, P.; Vieweg, H. Structure-activity relationships of inhibitors derived from 3-amidinophenylalanine. J. Enzyme Inhib. 1995, 9, 87-99.
26. Bergner, A.; Bauer, M.; Brandstetter, H.; Stürzebecher, J.; Bode, W. The X-ray crystal structure of thrombin in complex with Nα-2-naphthylsulfonyl-L-3-amidinophenylalanyl-4-methyl-piperidide: the beneficial effect of filling out an empty cavity. J. Enzyme Inhib. 1995, 9, 101-111.
27. Stürzebecher, J.; Vieweg, H.; Wikström, P. WO 94/18185, 1993.
28. Bode, W.; Turk, D.; Karshikov, A. The refined 1.9 Å X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human α-thrombin: Structure analysis, overall structure, elecctrostatic properties, detailed active-site geometry, and structure-function relationships. Protein Sci. 1992, 1, 426-471.
29. Abbreviations: F Xa, factor Xa; F XIIa, factor XIIa; APC, activated protein C; PK, plasma kallikrein; GK, glandular kallikrein; UK, urokinase; sc-tPA, single-chain tissue-type plasminogen activator; NMM, N-methylmorpholine; HOBt, hydroxybenzotriazole; DCC, N,N′-dicyclohexylcarbodiimide; DMF, N,N′-dimethylformamide; TEA, triethylamine; THF, tetrahydrofuran.
30. Deadman, J. J.; Elgendy, S.; Goodwin, C. A.; Green, D.; Baban, J. A.; Patel, G.; Skordalakes, E.; Chino, N.; Claeson, G.; Kakkar, V. V.; Scully, M. F. Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. J. Med. Chem. 1995, 38, 1511-1522.
31. Authors, unpublished results.
32. Hemker, H. C.; Willems, G. M.; Béguin, S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb. Haemostas. 1986, 56, 9-17.
33. Prasa, D.; Svendsen, L.; Stürzebecher, J. The ability of thrombin inhibitors to reduce the thrombin activity generated in plasma on extrinsic and intrinsic activation. Thromb. Haemostas. 1997, 77, 498-503.
34. Dixon, M. Determination of enzyme inhibitor constants. Biochem. J. 1953, 55, 170-171.
35. Walsmann, P. Über die Reinigung von Thrombinpräparaten. (On the purification of thrombin preparations.) Pharmazie 1968, 23, 401-402.
36. Stürzebecher, J.; Neumann, U.; Kohnert, U.; Kresse, G.-B.; Fischer, S. Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Protein Sci. 1992, 1, 1007-1013.